In this prospective, observational study we explored whether A118G single nucleotide polymorphism in the human -opioid receptor (MOR) gene could explain the inter-individual differences in opioid analgesic requirements in patients with acute postoperative pain and chronic pain. The frequency of the wild-type A118 MOR (major) and variant G118 MOR (minor) alleles in the subjects with chronic, noncancer pain (n ϭ 121) and opioid-naïve subjects with acute postoperative pain (n ϭ 101), serving as the control group, were examined. The relationships among the A118G MOR genotype, opioid requirements, and the numerical pain score were analyzed in both groups. The frequency of the minor allele was significantly lower in the subjects with chronic pain when compared with the group with acute postoperative pain (0.079 versus 0.158; P ϭ 0.009 by 2 test). No statistically significant association was observed between the presence of A118G MOR polymorphism and the average postoperative pain score or the doses of morphine used in the immediate postoperative period. In the high-quartile, opioid utilization, chronic pain patients, the homozygotic carriers of the major allele required significantly higher opioid dose than did the carriers of the minor allele. The results indicate that although the presence of the minor allele does not appear to affect opioid analgesic use in acute postoperative pain, the minor allele is less common in chronic pain patients, especially in those requiring higher doses of opioid analgesics. Some documented inter-individual differences in pain sensitivity and opioid analgesia are reported to be heritable as the result of polymorphisms (i.e., allelic variants) of pain-relevant genes (1,2). The human -opioid receptor (MOR), coded by the OPRM1 gene, is a primary candidate for the pharmacogenetic variability of the clinical effects of opioid analgesics because it is the major site of action for the most common opioids currently used (3,4). The most common single nucleotide polymorphism (SNP) of the MOR gene consists of the substitution of adenine (A) to guanine (G) at position 118 (A118G) of exon 1. This SNP leads to a substitution of the amino acid asparagine (Asn) to the negatively charged aspartate (Asp) at position 40 (Asn40Asp) of the extracellular N-terminus of the MOR. This results in the loss of a putative Nglycosylation site (one of five) within this region of the MOR. The functional consequences of this SNP have been investigated at the cellular and clinical levels (5,6). At the cellular level, very few studies have been undertaken to examine the effects of this SNP, and some of the conclusions appear conflicting. For instance, it has been reported that the SNP causes an increased affinity of the MOR for ␤-endorphin with increased potency of ␤-endorphin in eliciting receptor-mediated G-proteincoupled, inwardly rectifying potassium channel (GIRK) activity (7). On the other hand, a separate study has shown that ligand binding, as well as intracellular signaling processes after MOR activation, are not altered (8). In contrast to the unknown molecular consequences of the A118G mutation, several lines of evidence indicate that the presence of the SNP alters the clinical response to opioids (4,5). These clinical data indicate that carriers of the G118 MOR mutation (minor allele), when compared to the homozygous carrier of the major allele (A118), have a decreased response to clinical opioid potency, as shown for morphine and its active metabolite (morphine-6-glucuronide, M6G), decreased incidence of opioid-induced nausea and vomiting, as well as increased responsiveness of the hypothalamic-pituitaryadrenal axis to the antagonistic effect of naloxone (5,6,9 -11). The most recent study also indicates that
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We hypothesize that patients who are carriers of the minor allele for A118G MOR may differ not only in their response to the effectiveness of perioperative pain therapy (i.e., acute pain patients) but, most importantly, also in the effectiveness of opioid therapy in chronic pain patients.
The objective of the study was therefore to explore if differences in the frequency of the A118G SNP in the MOR genotype could provide a possible explanation for the differences in analgesic response produced by opioid analgesics in acute and chronic pain patients.
METHODS
After obtaining local IRB approval, 101 surgical patients undergoing elective laparoscopic abdominal surgery and 127 patients with chronic pain and receiving long-term treatment with opioid analgesics in the Pain Clinic at the Pennsylvania State University Milton S. Hershey Medical Center were enrolled between June and September 2004 into this prospective, observational study. Ethnicity of the subjects was determined by self-identification. IRB approved, informed, written consent was obtained from all enrolled patients before any study-related procedures being performed. The opioid-naïve group of patients without chronic pain but receiving opioids for surgery underwent various laparoscopic procedures under general endotracheal anesthesia maintained using volatile anesthetics (isoflurane, sevoflurane, or desflurane, no nitrous oxide), muscle relaxation with rocuronium or vecuronium supplemented with fentanyl and morphine administered intraoperatively (at the discretion of the primary anesthesia provider). All patients were tracheally extubated before transfer to the postanesthesia care unit (PACU).
Analgesia in the PACU was recorded by the attending nursing staff on arrival and at 5-min intervals until discharge from the unit. All subjects in the study were treated for pain in the PACU with morphine as the primary analgesic based on the evaluation of their pain by the nursing staff. In the chronic pain patient group, pain intensity and opioid analgesic requirements were assessed during their regular visit to the Chronic Pain Clinic. Pain intensity was measured using an 11-point verbal numerical rating scale (NRS) anchored by 0 ϭ no pain and 10 ϭ maximum imaginable pain. In the acute pain group, the maximum and average pain NRS was calculated for the entire PACU stay, whereas the chronic pain subject group was also asked to score their current pain intensity, worst pain intensity, and least pain intensity in the previous 24 h. Opioid consumption was calculated as the total dose of morphine administered during the entire PACU stay (acute pain patients) or the daily narcotic usage (chronic pain patients) converted into morphine sulfate equivalents (mg) using previously published conversion factors (13) .
Genotyping Procedures

Dna Collection And Extraction
Freshly drawn whole blood samples (approximately 0.12 mL) were spotted on IsoCode Cards (Schleicher & Schuell Inc., Keene, NH), dried overnight, placed in airtight foil bags with desiccant, and stored at room temperature until extraction. The extraction process (performed according to the manufacturer's recommendations) resulted in a DNA template for amplification, with an approximate yield of 0.95-1.8 g from 0.12 mL of blood.
Snp Genotyping DNA analysis of the DNA samples (in duplicate) was performed using the Assay-on-Demand™ SNP genotyping product (Applied Biosystems, Foster City, CA) based on the 5= nuclease assay according to the manufacturer's protocol. Briefly, isolated DNA was incubated with two flanking primers (forward and reverse) for amplification of the sequence of interest and two TaqMan™ MGB probes for detecting specific alleles containing a fluorescent reporter dye (VIC and FAM) at the 5= end of each allele specific probe and nonfluorescent quencher at the 3= end of the probe. The real-time polymerase chain reaction (PCR) analysis was performed using TaqMan Universal Master Mix, No AmpErase™ UNG in 96-well optical plate using an ABI Prism 7700 Sequence Detection System (PSHMC Genomic Core Facilities). The amplification conditions include holding (10 min, 95°C), followed by 40 cycles of 15-s denaturation at 92°C and annealing/extension at 60°C. After PCR amplification, end-point fluorescence measurements from each well were obtained. Based on the observed fluorescence measurements, the presence or absence of either one of two copies of the A118 and G118 MOR allele was determined in each sample. The type of fluorescence of the end-product for the PCR reaction indicated the type of MOR allele in the investigated DNA sample (e.g., the presence of only one type of fluorescence indicates homozygotes for either MOR wild-type or G118 MOR allele and, conversely, the presence of two different amplified fluorescence products indicates heterozygotes for the investigated alleles).
Calibration and Verification of SNP Assay
The presence or absence of the minor allele coding for A118G was confirmed by the direct automatic sequencing method for several representative samples containing G118 allele (as determined by the TaqMan real-time PCR) using designed primers and generated PCR template of MOR exon 1 using an ABI Prism 377 Automatic Sequencer in the PSHMC Core Facilities. In addition, the TaqMan real-time PCR discrimination sensitivity was verified by including samples containing human opioid receptor (wild-type, A118) cloned into pcDNA3.1ϩ (Invitrogen) at restyriction sites Kpnl (5=) and Xhol (3=), generously provided by the Guthrie Research Institute (Sayre, PA). To construct plasmid with 118 AϾG mutated insert, pcDNA3.1ϩ containing A118 MOR cDNA was transfected into electrocompetent Escherichia coli by electroporation, and recombinants were selected using ampicillin-containing agar plates. The MOR receptor A118 cDNA fragment sub-cloned into pcDNA3.1 was used as a template for site-directed mutagenesis (A-ϾG118) performed by a custom mutagenesis service (Top Gene Technologies, Inc, Montreal, Canada).
Statistical Analysis
The primary outcome measures in the study were represented by the total postoperative morphine in the immediate postoperative period (acute pain group) and total dose of opioid analgesics (expressed in morphine equivalents per 24-h period) administered to patients with chronic pain. The calculation of sample size in both groups was based on a power calculation using previous data indicating that a minimum number of 90 subjects in the acute pain group and 120 in the chronic pain group is required (assuming the ratio 3:1 of the carriers of wild-type MOR to the carriers of the variant allele) to achieve 80% power (type II error at 0.2) to detect a clinically relevant change by 50% or more in the doses of opioid analgesics, with ␣ ϭ 0.05. 2 analysis or Fisher's exact test was used to compare genotype and allele frequencies between acute and chronic pain patients and to determine deviation from Hardy-Weinberg equilibrium. Power analyses were conducted for each 2 analysis, with ␣ set at 0.05 for a two-tailed test. For analyses of genotypes, power to detect a 15% rate difference between groups was estimated. For analyses of allele frequencies, power to detect a 10% rate difference was estimated. The demographic and perioperative data were compared using 2 and Mann-Whitney U-test. Statistical significance was set at 0.05.
RESULTS
The MOR genotype distribution in acute pain patient samples was in Hardy-Weinberg equilibrium (P ϭ 0.25, Fisher's Exact test). The MOR A118G SNP genotype and allele frequency in this group of patients was similar (major allele, A118 ϭ 0.842 and minor allele, G118 ϭ 0.158) to previously published data examining MOR A118G SNP in a Caucasian population (14) . Only one study subject was homozygous for the minor allele and was therefore analyzed together with the heterozygotic carriers of the G118 allele.
Although more females than males were enrolled in the acute postoperative pain group (77% versus 23%, respectively), no statistically significant differences (P ϭ 0.79, Fisher's exact test, two-tailed) were observed in the distribution pattern of the A118G MOR allele among the participants. The perioperative data obtained for this control group are summarized in Table 1 . No differences in the intraoperative opioid or the total administered dose of morphine during the postoperative stay in PACU were noted between carriers of the A118 MOR or the G118 MOR allele. Similarly, no differences in the average postoperative pain score were noted between the subjects carrying A118 MOR or G118 MOR allele during the postoperative recovery in PACU. The results of the analysis of possible correlation between greater intraoperative narcotic doses and pain scores (NRS) or morphine use in PACU indicate that there was no statistically significant correlation between the intraoperative use of morphine and fentanyl versus postoperative average NRS (analysis of variance, P ϭ 0.173 and P ϭ 0.449, respectively) or postoperative use of morphine (analysis of variance, P ϭ 0.12 and P ϭ 0.1, respectively) in the investigated population of patients with postoperative pain.
The chronic pain population investigated in this study consisted of 121 patients treated for longer than 3 mo in the Chronic Pain Clinic for a variety of chronic noncancer pain conditions and seen in the Pain Clinic in the time coinciding with the enrollment of the control group of surgical patients. All investigated patients were being treated with opioid analgesics at the time of the study visit and were generally classified into 3 broad treatment groups based on the type of pharmacological treatment (oral opioid analgesics 80.2%, fentanyl patch 13.1%, and intrathecal opioid analgesics 6.6%). The classification of the pain syndromes at the time of the study visit included chronic failed back syndrome (61.9%), myofascial pain (9.1%), complex regional pain syndrome type I or II (11.6%), and all other types (17.7%) in individually relatively small numbers.
The genotyping data for the chronic pain population is provided in Table 2 . The MOR A118G genotype distribution in chronic pain patient samples was in Hardy-Weinberg equilibrium (P ϭ 0.79, 2 test). No statistically significant differences (P ϭ 0.55, Fisher's exact test, two-tailed) were observed in the distribution pattern of the A118G MOR allele between female and male participants in the study. The frequency of the G118 MOR allele was approximately 50% lower in the group of patients with chronic pain when compared with the group of patients with acute postoperative pain, serving as control 0.079 versus 0.158, respectively (P ϭ 0.009, 2 test). There was no difference in the frequency of the minor allele within the chronic pain treatment groups, which were stratified according to the type of pharmacological treatment (i.e., patients treated with oral opioid analgesics, fentanyl patch, and intrathecal opioid analgesics) ( Table  3) . On the other hand, the difference in the frequency of minor allele was significantly less in the group treated with the oral opioid analgesics when compared with the control (acute pain) group. No statistically significant differences in the frequency of the minor allele were found when comparing chronic patient groups treated with fentanyl patch or intrathecal opioid analgesic infusion with the control group; however, the lack of statistical significance for these comparisons may be related to the small number of patients in each group.
There was no significant difference in opioid usage (expressed in morphine equivalents) was noted in the carriers of the G118 MOR allele in the chronic pain group when compared to those homozygous for the wild-type type allele (Fig. 1) . Although no differences in the median dose of opioids was noted in these df ϭ 1 for all analyses; Chi 2 ϭ Pearson Chi-square test; P ϭ probability of type I error; OR ϭ odds ratio; 95%CI ϭ 95% confidence interval of OR.
groups (P Ͼ 0.05, Mann-Whitney U-test), the scatter of the data, and in particular the number of chronic patients consuming morphine-equivalent doses above the 75 th percentile of chronic pain patients was higher in the carriers of the major allele. In fact, the mean opioids dose in this higher quartile was significantly larger in the homozygous carriers of the wild-type MOR allele when compared with the carriers of the G118 MOR variant allele (750.5 Ϯ 544 versus 412 Ϯ 41 mg of morphine equivalents; P Ͻ 0.005 by Student's t-test). No statistically significant differences in the average verbal pain scores (analyzed as current, best, and worst pain) were noted in the carrier of the minor allele versus homozygotes for the major allele (Fig. 2) .
DISCUSSION
The results of the present study demonstrate that frequency of the minor allele (G118 MOR) for the A118G SNP of the MOR gene was significantly less in the group of opioid-treated, chronic pain patients when compared to the opioid-naïve acute postoperative group of patients without chronic pain. These results indicate that the G118 MOR allele seems to be associated with a "protective" effect against chronic pain, and may alter the response to opioid analgesics in chronic pain patients. A strong argument for this possibility is the fact that there is a consistent trend for higher frequencies of the A118/A118 genotype and major allele in chronic pain patients apparently resistant to high-dose opioids. In this subgroup of chronic pain patients in the high quartile of opioid use (i.e., consuming morphine-equivalent doses above the 75 th percentile of all chronic pain patients), the homozygous carriers of the wild-type MOR allele required significantly more opioids than the carriers of the variant MOR.
The mechanism of the association between the A118G genotype of OPRM1 and chronic pain is unknown. One potential explanation is that the variant receptor may be associated with altered opioid signaling on the cellular level (7). This enhanced opioid signaling might produce changes in the tonic activity of the opioid system, leading to an increase in the pain threshold and/or increased effectiveness of opioid analgesics. In other words, the carriers of the mutated MOR will need less opioid to produce a similar pharmacological response when compared with the subjects homozygous for the wild-type MOR. This possibility is supported by the results of a recent experimental study in which the carriers of the minor allele had significantly higher pressure pain thresholds than those homozygous for the common allele (12) . In this latter study, a sex-by-genotype interaction emerged for thermal pain ratings, such that the minor allele was associated with lower pain ratings among men but higher pain ratings among women. The results of our study did not reveal any differences in genotype frequencies, pain rating, or opioid dosage in the study groups when analyzed by gender. Moreover, recent results in an obstetric patient population indicate that heterozygous carriers of the A118G SNP demonstrated a highly significant (1.68-fold) enhancement of intrathecal fentanyl's effect for labor analgesia when compared with the homozygous carriers of the wild-type MOR allele (15) . There were conflicting results of studies investigating the association between A118G SNP and morphine requirements in patients with pain caused by malignant disease (16) . The latter study reported that patients heterozygous for A118G SNP presented with higher pain ratings than homozygous subjects for both minor and major allele. In addition, the homozygous carriers of the minor allele required a significantly higher total daily dose of morphine than either heterozygous or homozygous carriers for the wild-type allele. However, in the cited study, only 4 subjects were homozygous for the G118 MOR allele; therefore, this purported difference among all 3 genotypes is still not fully elucidated and deserves further investigation in a larger sample of G118 MOR homozygotes.
The A118G SNP displayed contradictory findings in human experimental studies on opioid efficacy after IV administration of morphine and its active metabolite, M6G (17) . Although the presence of A118G SNP was found to decrease the pharmacological activity of M6G, the presence of this polymorphism produced conflicting results for morphine itself (10, 11, 18) . In summary, the existing studies do not present clear and reproducible evidence for the associations among A118G SNP, pain threshold, and pharmacological effects of opioids.
Based on the previously published association studies of the A118G SNP in substance abuse disorders, the pattern of results raises an alternative possibility that the MOR gene may also function as a general-risk gene for substance abuse rather than a specific-risk gene for chronic pain or opioid treatment resistance. These suggestions are based on the fact that in drug addiction, the opioid system is thought to mediate motivational effects through dopamineindependent mechanisms. MOR, through its effects on reward and stress-response, modulates alcohol intake in both animal and human laboratory studies. It was reported that A118G SNP is significantly associated with alcohol dependency (19) , methamphetamine abuse (20) , and heroin dependence (7, 21) . On the other hand, several groups reported lack of association between A118G SNP and alcohol and heroin abuse (22) . Because our chronic pain subject sample consisted of patients undergoing long-term, high-dose opioid pharmacotherapy, it is also possible that the observed changes in the frequency of the A118G SNP between chronic pain and control patients maybe explained, in part, by the contribution of the MOR gene to risk for substance dependence.
Presently, the exact molecular consequence of the A118G SNP on the MOR function that may explain the observed clinical effects of this polymorphism remains unknown. The most commonly accepted explanation (and almost universally cited in published studies related to the A118G SNP) is a higher affinity of the mutant MOR for ␤-endorphin. A subsequent study has reported no difference in the binding characteristics of ligands to the mutant MOR (8) . Recent data indicate that A118G may produce deleterious effects on both mRNA and corresponding MOR protein yield in both transfected cellular and human autopsy brain tissue from carriers of A118G SNP (23) .
Further studies are obviously needed to clarify the exact molecular mechanisms associated with the altered opioid signaling in carriers of the A118G MOR mutations.
In summary, although the presence of the minor allele (G118 MOR) does not appear to affect the use of morphine or other opioids in either acute postoperative pain or chronic pain, the minor allele is less common in chronic pain patients, especially in those requiring high-dose opioids.
